Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Not available.
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-03-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11970 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850033561640370176 |
|---|---|
| author | Enrica Antonia Martino Annalisa Pitino Massimo Offidani Roberta Della Pepa Alessandro Gozzetti Velia Bongarzoni Antonio Maroccia Valeria Amico Paola Stefanoni Elena Zamagni Sofia Terlizzi Daniele Derudas Salvatore Palmieri Rosario Bianco Concetta Conticello Marino Brunori Angela Rago Flavia Lotti Raffaele Fontana Nicola Sgherza Elena Rossi Anna Maria Cafro Massimiliano Arangio Febbo Angela Maria Quinto Claudio Cerchione Gloria Margiotta Casaluci Annalisa Citro Catello Califano Renato Zambello Silvia Mangiacavalli Carmine Liberatore Gabriele Buda Claudio De Magistris Angela Amendola Ernesto Vigna Antonella Bruzzese Emiliano Barbieri Micol Quaresima Daniela Roccotelli Francesca Farina Jacopo Micozzi Iolanda Donatella Vincelli Giuseppe Tarantini Elisabetta Antonioli Sara Aquino Alessandro Maggi Alessandra Lombardo Giuseppe Bertuglia Anna Furlan Anna Mele Ombretta Annibali Emilia Cotzia Pietro Benvenuti Lorenzo De Paoli Gregorio Barilà Sonia Morè Valerio De Stefano Francesco Di Raimondo Maria Teresa Petrucci Niccolò Bolli Pellegrino Musto Antonino Neri Fortunato Morabito Giovanni Tripepi Massimo Gentile |
| author_facet | Enrica Antonia Martino Annalisa Pitino Massimo Offidani Roberta Della Pepa Alessandro Gozzetti Velia Bongarzoni Antonio Maroccia Valeria Amico Paola Stefanoni Elena Zamagni Sofia Terlizzi Daniele Derudas Salvatore Palmieri Rosario Bianco Concetta Conticello Marino Brunori Angela Rago Flavia Lotti Raffaele Fontana Nicola Sgherza Elena Rossi Anna Maria Cafro Massimiliano Arangio Febbo Angela Maria Quinto Claudio Cerchione Gloria Margiotta Casaluci Annalisa Citro Catello Califano Renato Zambello Silvia Mangiacavalli Carmine Liberatore Gabriele Buda Claudio De Magistris Angela Amendola Ernesto Vigna Antonella Bruzzese Emiliano Barbieri Micol Quaresima Daniela Roccotelli Francesca Farina Jacopo Micozzi Iolanda Donatella Vincelli Giuseppe Tarantini Elisabetta Antonioli Sara Aquino Alessandro Maggi Alessandra Lombardo Giuseppe Bertuglia Anna Furlan Anna Mele Ombretta Annibali Emilia Cotzia Pietro Benvenuti Lorenzo De Paoli Gregorio Barilà Sonia Morè Valerio De Stefano Francesco Di Raimondo Maria Teresa Petrucci Niccolò Bolli Pellegrino Musto Antonino Neri Fortunato Morabito Giovanni Tripepi Massimo Gentile |
| author_sort | Enrica Antonia Martino |
| collection | DOAJ |
| description |
Not available.
|
| format | Article |
| id | doaj-art-6aaf6e0e8f6049e8aa5fe189ff71206d |
| institution | DOAJ |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-6aaf6e0e8f6049e8aa5fe189ff71206d2025-08-20T02:58:10ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-03-01999110.3324/haematol.2025.287325Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world dataEnrica Antonia Martino0Annalisa Pitino1Massimo Offidani2Roberta Della Pepa3Alessandro Gozzetti4Velia Bongarzoni5Antonio Maroccia6Valeria Amico7Paola Stefanoni8Elena Zamagni9Sofia Terlizzi10Daniele Derudas11Salvatore Palmieri12Rosario Bianco13Concetta Conticello14Marino Brunori15Angela Rago16Flavia Lotti17Raffaele Fontana18Nicola Sgherza19Elena Rossi20Anna Maria Cafro21Massimiliano Arangio Febbo22Angela Maria Quinto23Claudio Cerchione24Gloria Margiotta Casaluci25Annalisa Citro26Catello Califano27Renato Zambello28Silvia Mangiacavalli29Carmine Liberatore30Gabriele Buda31Claudio De Magistris32Angela Amendola33Ernesto Vigna34Antonella Bruzzese35Emiliano Barbieri36Micol Quaresima37Daniela Roccotelli38Francesca Farina39Jacopo Micozzi40Iolanda Donatella Vincelli41Giuseppe Tarantini42Elisabetta Antonioli43Sara Aquino44Alessandro Maggi45Alessandra Lombardo46Giuseppe Bertuglia47Anna Furlan48Anna Mele49Ombretta Annibali50Emilia Cotzia51Pietro Benvenuti52Lorenzo De Paoli53Gregorio Barilà54Sonia Morè55Valerio De Stefano56Francesco Di Raimondo57Maria Teresa Petrucci58Niccolò Bolli59Pellegrino Musto60Antonino Neri61Fortunato Morabito62Giovanni Tripepi63Massimo Gentile64Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, CosenzaInstitute of Clinical Physiology (IFC-CNR), RomeHematology Unit, AOU delle Marche, AnconaDepartment of Clinical Medicine and Surgery, University Federico II, NaplesDepartment of Medicine, Surgery and Neurosciences, University of Siena Policlinico S Maria alle Scotte, SienaUOC of Hematology San Giovanni-Addolorata Hospital RomeHematology Unit - Ospedale dell'Angelo Azienda ULSS n.3 Serenissima, Venezia MestreUOSD Ematologia, AORN San Pio, BeneventoHematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, BergamoIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, BolognaDepartment of Hematology ASST Spedali Civili di Brescia, BresciaDepartment of Hematology, Businco Hospital, CagliariHematology Unit, Ospedale Cardarelli, NapoliHematology, Hospital "Sant'Anna e San Sebastiano", CasertaDivision of Hematology, Azienda Policlinico-S. Marco, University of Catania, CataniaInternal Medicine, Ospedale Santa Croce, FanoUOSD Ematologia ASL Roma 1, RomeInstitute of Hematology, TMO Azienda Universitaria-Ospedaliera Santa Maria della Misericordia di Perugia, PerugiaHematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", SalernoUnit of Hematology and Stem Cell Transplantation, AOUC Policlinico, BariSection of Hematology, Catholic University, Fondazione Policlinico Gemelli IRCCS, RomeDepartment of Hematology, GOM Niguarda Hospital, MilanOnco Hematology Unit, Veneto Institute of Oncology IOV-IRCCS, PaduaHaematology and Transplant Unit, IRCCS - Istituto Tumori "Giovanni Paolo II", BariDepartment of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-CesenaDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, NovaraHematology Unit, Legnano General Hospital, Legnano (Milan)Onco-Hematology Unit, "A. Tortora" Hospital, PaganiDepartment of Medicine (DIMED), Hematology and Clinical Immunology, Padua University School of Medicine, PadovaDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, PaviaHematology Unit, Department of Oncology and Hematology, Ospedale Santo Spirito, Pescara, Italy; Department of Medicine and Aging Sciences, University of Chieti-Pescara, ChietiDepartment of Clinical and Experimental Medicine, Hematology, University of Pisa, PisaHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, MilanHematology Unit, Azienda Ospedaliera Regionale "San Carlo", PotenzaDepartment of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, CosenzaDepartment of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, CosenzaHematology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, ModenaHematology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio EmiliaDepartment of Hematology and Bone Marrow Transplant, IRCSS Casa Sollievo Della Sofferenza, San Giovanni RotondoHematology and BMT Unit, IRCCS Ospedale San Raffaele, MilanDepartment of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, RomeDepartment of Hemato-Oncology and Radiotherapy, Hematology Unit, Great Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio CalabriaHematology Unit, "Dimiccoli" Hospital, Barletta (BAT)Haematology Unit Careggi University Hospital, FlorenceHematology and Hematopoietic Stem Cell Transplantation Unit, IRCCS Ospedale Policlinico San Martino, GenoaHaematology, Ospedale G. Moscati, TarantoOnco-hematology Unit Azienda Ospedaliera Santa Maria of Terni, TerniDivision of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, University of Torino, TorinoDivision of Hematology Ospedale Ca' Foncello di Treviso, ASL 2, TrevisoHaematology, Ospedale Cardinale Panico, Tricase (Lecce)Hematology, stem cell transplantation, Fondazione Policlinico Universitario Campus Bio medico di Roma, RomeSection of Hematology-Ospedale E. Muscatello Augusta, SiracusaDepartment of Medicine and Surgery, University of Insubria and Department of Oncology, ASST Sette Laghi, Ospedale di Circolo, VareseDivision of Hematology, Ospedale Sant'Andrea, VercelliHematology Unit, Ospedale San Bortolo, VicenzaHematology Unit, AOU delle Marche, AnconaSection of Hematology, Catholic University, Fondazione Policlinico Gemelli IRCCS, RomeDivision of Hematology, Azienda Policlinico-S. Marco, University of Catania, CataniaDepartment of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, RomeHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, MilanDepartment of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, BariScientific Directorate, Azienda USL-IRCCS of Reggio Emilia, Reggio EmiliaGruppo Amici Dell'Ematologia Foundation-GrADE, Reggio EmiliaInstitute of Clinical Physiology (IFC-CNR), Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria, Reggio CalabriaDepartment of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy; Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende Not available. https://haematologica.org/article/view/11970 |
| spellingShingle | Enrica Antonia Martino Annalisa Pitino Massimo Offidani Roberta Della Pepa Alessandro Gozzetti Velia Bongarzoni Antonio Maroccia Valeria Amico Paola Stefanoni Elena Zamagni Sofia Terlizzi Daniele Derudas Salvatore Palmieri Rosario Bianco Concetta Conticello Marino Brunori Angela Rago Flavia Lotti Raffaele Fontana Nicola Sgherza Elena Rossi Anna Maria Cafro Massimiliano Arangio Febbo Angela Maria Quinto Claudio Cerchione Gloria Margiotta Casaluci Annalisa Citro Catello Califano Renato Zambello Silvia Mangiacavalli Carmine Liberatore Gabriele Buda Claudio De Magistris Angela Amendola Ernesto Vigna Antonella Bruzzese Emiliano Barbieri Micol Quaresima Daniela Roccotelli Francesca Farina Jacopo Micozzi Iolanda Donatella Vincelli Giuseppe Tarantini Elisabetta Antonioli Sara Aquino Alessandro Maggi Alessandra Lombardo Giuseppe Bertuglia Anna Furlan Anna Mele Ombretta Annibali Emilia Cotzia Pietro Benvenuti Lorenzo De Paoli Gregorio Barilà Sonia Morè Valerio De Stefano Francesco Di Raimondo Maria Teresa Petrucci Niccolò Bolli Pellegrino Musto Antonino Neri Fortunato Morabito Giovanni Tripepi Massimo Gentile Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data Haematologica |
| title | Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data |
| title_full | Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data |
| title_fullStr | Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data |
| title_full_unstemmed | Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data |
| title_short | Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data |
| title_sort | comparison of isatuximab pomalidomide dexamethasone i versus i elotuzumab pomalidomidedexamethasone in relapsed refractory multiple myeloma patients a target trial emulation using real world data |
| url | https://haematologica.org/article/view/11970 |
| work_keys_str_mv | AT enricaantoniamartino comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT annalisapitino comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT massimooffidani comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT robertadellapepa comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT alessandrogozzetti comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT veliabongarzoni comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT antoniomaroccia comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT valeriaamico comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT paolastefanoni comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT elenazamagni comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT sofiaterlizzi comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT danielederudas comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT salvatorepalmieri comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT rosariobianco comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT concettaconticello comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT marinobrunori comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT angelarago comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT flavialotti comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT raffaelefontana comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT nicolasgherza comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT elenarossi comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT annamariacafro comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT massimilianoarangiofebbo comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT angelamariaquinto comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT claudiocerchione comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT gloriamargiottacasaluci comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT annalisacitro comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT catellocalifano comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT renatozambello comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT silviamangiacavalli comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT carmineliberatore comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT gabrielebuda comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT claudiodemagistris comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT angelaamendola comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT ernestovigna comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT antonellabruzzese comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT emilianobarbieri comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT micolquaresima comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT danielaroccotelli comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT francescafarina comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT jacopomicozzi comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT iolandadonatellavincelli comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT giuseppetarantini comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT elisabettaantonioli comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT saraaquino comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT alessandromaggi comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT alessandralombardo comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT giuseppebertuglia comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT annafurlan comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT annamele comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT ombrettaannibali comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT emiliacotzia comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT pietrobenvenuti comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT lorenzodepaoli comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT gregoriobarila comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT soniamore comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT valeriodestefano comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT francescodiraimondo comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT mariateresapetrucci comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT niccolobolli comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT pellegrinomusto comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT antoninoneri comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT fortunatomorabito comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT giovannitripepi comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata AT massimogentile comparisonofisatuximabpomalidomidedexamethasoneiversusielotuzumabpomalidomidedexamethasoneinrelapsedrefractorymultiplemyelomapatientsatargettrialemulationusingrealworlddata |